Xencor adds $15M to fifth VC round

Oxford Bioscience Partners and Merlin Nexus joined Novo Nordisk in pumping $15 million more into Xencor's Series E, bringing the grand total to $60 million. Xencor is developing new therapies for Hodgkin's disease, T-cell lymphoma, cancer and inflammatory diseases. To date, Xencor has raised $142 million for its pipeline work. Xencor was a 2005 Fierce 15 company.

- check out Xencor's release on the round
- see the report from SoCalTech

Related Article:
Xencor pockets $45M in new funding round. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.